Upgrade to SI Premium - Free Trial

Veru (VERU) is Top Pick, Little Doubt in EUA for sabizabulin - Oppenheimer Bullish on Shares Ahead of FDA Decision

July 11, 2022 5:50 AM
(Updated - July 11, 2022 7:15 AM EDT)Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $36.00 price target on ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)


Analyst Comments Hot Comments